Medical Abortion, Complete or Unspecified, Without Complication Clinical Trial
Official title:
Piloting an Innovation to Improve the Quality of Remote Abortion Services: Incorporating Use of Multi-Level Pregnancy Tests
| NCT number | NCT03207880 |
| Other study ID # | 6011 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | November 1, 2017 |
| Est. completion date | August 10, 2018 |
| Verified date | September 2018 |
| Source | Gynuity Health Projects |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Serial use of urine multi-level pregnancy tests (MLPTs) has been shown to be a reliable and
efficient strategy for excluding ongoing pregnancy after medical abortion at ≤ 63 days of
gestation. This pilot project will assess whether MLPTs can enhance the quality of remote
medical abortion services through enabling women to reliably ascertain their abortion
outcomes at home sooner than would otherwise have been the case.
safe2choose provides remote medical abortion services through the Internet (information,
counselling and access to abortion pills) in a growing number of countries worldwide.
safe2choose will collaborate with Gynuity Health Projects to pilot the utility of MLPTs for
home follow-up as part of its remote medical abortion services.
As safe2choose does not have a physical office, the location of the sponsor's office is
listed in this entry as the study location. Women from the United States are NOT eligible to
enroll.
| Status | Completed |
| Enrollment | 165 |
| Est. completion date | August 10, 2018 |
| Est. primary completion date | August 10, 2018 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | N/A to 50 Years |
| Eligibility |
Inclusion Criteria: - Recipient of safe2choose medical abortion services - Able to read English or Spanish - = 56 days LMP - Willing and able to read and sign consent form - Agree to comply with the study procedures, including completing the follow-up survey Exclusion Criteria: - Does not meet inclusion criteria |
| Country | Name | City | State |
|---|---|---|---|
| United States | Gynuity Health Projects | New York | New York |
| Lead Sponsor | Collaborator |
|---|---|
| Gynuity Health Projects | safe2choose |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Proportion of women who successfully receive the MLPTs | 1 week after mailing the MLPTs | ||
| Primary | Proportion of women who use the MLPTs to determine their abortion outcome | 2 weeks after receiving medical abortion package | ||
| Primary | Proportion of women able to use MLPTs on their own without guidance or instruction from providers | 2 weeks after receiving medical abortion package | ||
| Primary | Proportion of women who take action based on the interpretation of their test results | 2 weeks after receiving medical abortion package | ||
| Primary | Proportion of women who are satisfied with using MLPTs | 2 weeks after receiving medical abortion package | ||
| Secondary | Proportion of all eligible safe2choose clients who elect to participate in the study | 0 days after recruitment | ||
| Secondary | Proportion of women who find the MLPT instructions (written and video) to be helpful tools | 2 weeks after enrollment |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04160221 -
Second Trimester Medical Abortion
|
N/A | |
| Terminated |
NCT01615211 -
Randomized Study of Letrozole and Trilostane for Medical Abortion
|
Phase 2 |